These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Viridian Therapeutics, Inc. VRDN reported upbeat results for the second quarter on Wednesday.The company posted quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.02) per share. The company reported quarterly sales of $75.000 thousand which beat the analyst consensus estimate of $43.643 thousand.“Veligrotug’s recent Breakthrough Therapy Designation as well as the continued and consistent performance of veligrotug across all of the endpoints and timepoints in our pivotal c ...